Study to be given combined modality therapy with medication and surgery, the radiotherapy for prostate cancer with oligometastases of bone

Multi-institutional study aimed at radical cure with multidisciplinary treatment including preoperative endocrine chemotherapy (LHRH analog, denosumab, apalutamide, tegafur / uracil), robot-assisted total prostatectomy and radiation therapy for prostate cancer with oligometastases of bone - Multi-institutional study aimed at radical cure with multidisciplinary treatment including preoperative endocrine chemotherapy, robot-assisted total prostatectomy and radiation therapy for prostate cancer with oligometastases of bone

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000046430

Enrollment

Registered

2022-12-22

Start date

2021-12-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Prostate cancer

Interventions

LHRH analog, denosumab, Apalutamide, UFT For 6 months or more robot-assisted radical prostatectomy Radiation therapy for metastases

Eligibility

Sex/Gender

Male

Inclusion criteria

Inclusion criteria: Male prostate cancer patients with bone oligometastases

Exclusion criteria

Exclusion criteria: Patients with 4 or more bone metastases Patients with multiple lymph node metastases

Design outcomes

Primary

Measure	Time frame
Progression free survial	—

Secondary

Measure	Time frame
Overall survival Disease specific survival Adverse events	—

Countries

Japan

Contacts

Public ContactMakoto Kawase

Gifu University Graduate School of Medicine/School of Medicine Urology

kawase.makoto.g5@f.gifu-u.ac.jp058-230-6338

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026